Identification of human pregnane X receptor antagonists utilizing a high-throughput screening platform
Authors:
Open Access
- 23 October 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1448744
Abstract
Pregnane X receptor (PXR) is a xenobiotic-sensing nuclear receptor with a well-established role in regulating drug metabolism and clearance. Recent studies have shown that PXR is involved in cell proliferation, apoptosis, immune response, and energy homeostasis. It is important to identify compounds that may modulate PXR activity to prevent drug-drug interactions, distinguish chemicals which could potentially generate toxicity, and identify compounds for further development towards therapeutic usage. In this study, we have screened the National Center for Advancing Translational Sciences (NCATS) Pharmacologically Active Chemical Toolbox (NPACT) library, which consists of 5,099 unique pharmacologically active synthetic and naturally derived small molecules to identify PXR antagonists. Ninety-four compounds were identified as potential PXR antagonists through a primary screen and 66 were confirmed in a confirmation study. Of these compounds, twenty potential PXR antagonists, including gamma-secretase modulator 2 (GSM2) and fusidic acid, were selected for further study based on their efficacy, potency, and novelty. Their PXR inhibition abilities were assessed by examining their effects on cytrochrome P450 (CYP) 3A4 mRNA expression using metabolically competent HepaRG cells. Additionally, a pharmacological inhibition assay using various concentrations of rifampicin as a stimulator was performed in HepG2-CYP3A4-hPXR cells to confirm the activity of the 20 selected compounds against PXR. Finally, HepaRG cells were used to confirm PXR antagonism by verification of a concentration-dependent decrease of CYP3A4 when co-treated with the known PXR agonist, rifampicin. Additionally, the potent actives were further investigated using molecular docking to find the potential interactions of the novel ligands with the active sites of hPXR. To our knowledge from the current study, GSM2 and fusidic acid have been identified as novel PXR antagonists, which provides useful information for further investigation regarding possible drug-drug interactions, as well as the detection of potential therapeutic effects or other toxic consequences.Keywords
This publication has 37 references indexed in Scilit:
- Building a Chemical Toolbox for Human Pregnane X Receptor Research: Discovery of Agonists, Inverse Agonists, and Antagonists Among Analogs Based on the Unique Chemical Scaffold of SPA70Journal of Medicinal Chemistry, 2021
- SPA70 is a potent antagonist of human pregnane X receptorNature Communications, 2017
- A Quantitative High-Throughput Screening Data Analysis Pipeline for Activity Profiling2016
- Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeysBioorganic & Medicinal Chemistry Letters, 2015
- Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureusInternational Journal of Antimicrobial Agents, 2012
- Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxinsCell Biology and Toxicology, 2012
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Synaptic transmission block by presynaptic injection of oligomeric amyloid betaProceedings of the National Academy of Sciences, 2009
- Self-organizing neural projectionsNeural Networks, 2006
- A drug interaction between fusidic acid and a combination of ritonavir and saquinavirBritish Journal of Clinical Pharmacology, 2000